Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria
June 16 2023 - 12:18AM
Business Wire
Naim Alkhouri, MD, FAASLD, to Present Findings
from Non-alcohol Related Fatty Liver Disease Feasibility Study
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing a clinically validated,
software-based, novel form of cognitive behavioral therapy (CBT) to
address the root causes of cardiometabolic diseases, today
announced the details of its poster presentation at the European
Association for the Study of the Liver (EASL) Congress 2023, being
held from June 21-24 in Vienna, Austria. EASL is a leading
professional society and their clinical practice guidelines inform
the standard of care for Non-alcohol Related Fatty Liver Disease
(NAFLD) and non-alcoholic steatohepatitis (NASH) around the
world.
Naim Alkhouri, MD, FAASLD, Director of the Fatty Liver Program
at Arizona Liver Health and Principal Investigator of the study,
will present the results from the LivVita Study. The study was
designed in partnership with Better Therapeutics to explore the
safety, efficacy, and usability of a novel PDT platform, in
individuals with NAFLD or NASH. Currently, there is no FDA approved
treatment for NAFLD and NASH, which affect approximately one in
four Americans. Behavioral change is foundational to addressing the
root causes of the diseases and topline results demonstrate a
prescription CBT treatment option could be of significant
benefit.
Following the successful completion of the LivVita Liver Study,
Better Therapeutics commenced work on an application to the FDA for
Breakthrough Device Designation. Topline results from the LivVita
Study from Better Therapeutics’ public announcement can be viewed
here.
Details of the presentation are as follows:
Presentation Title: A novel prescription digital
therapeutic for the treatment of non-alcohol related fatty liver
disease: feasibility study Session Date: June 23 Poster
Board Number: 818
The full text of the abstract is published in the EASL Congress
digital Abstract Book on pg. S822.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The Company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for T2D, heart disease and
other conditions. The CBT delivered by Better Therapeutics’ PDT is
designed to enable changes in neural pathways of the brain so
lasting changes in behavior become possible. Addressing the
underlying causes of these diseases has the potential to
dramatically improve patient health while lowering healthcare
costs. Better Therapeutics’ clinically validated mobile
applications, if authorized for marketing, are intended to be
prescribed by physicians and reimbursed like traditional
medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are
"forward-looking statements" within the meaning of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are typically
identified by words such as “plan,” “believe,” “expect,”
“anticipate,” “intend,” “outlook,” “estimate,” “forecast,”
“project,” “continue,” “could,” “may,” “might,” “possible,”
“potential,” “predict,” “should,” “would” and other similar words
and expressions, but the absence of these words does not mean that
a statement is not forward-looking. The forward-looking statements
in this press release include, but are not limited to, statements
regarding Better Therapeutics’ plans and expectations regarding FDA
submissions, including its application for Breakthrough Device
designation for its investigational prescription digital therapy in
NAFLD and NASH, expectations related to the potential benefits of a
prescription CBT treatment option and its potential treatment
applications, Better Therapeutics’ plans regarding the research and
advancement of its product candidates for additional treatments,
Better Therapeutics’ plans regarding publications, and potential
partnerships opportunities to accelerate the development of PDTs,
among others. These forward-looking statements are based on the
current expectations of the management of Better Therapeutics and
are inherently subject to uncertainties and changes in
circumstances and their potential effects and speak only as of the
date of such statement. There can be no assurance that future
developments will be those that have been anticipated. These
forward-looking statements involve a number of risks, uncertainties
or other assumptions that may cause actual results or performance
to be materially different from those expressed or implied by these
forward-looking statements including: risks related to Better
Therapeutics’ business, such as the willingness of the FDA to
authorize PDTs, including BT-001, for commercial distribution and
insurance companies to reimburse their use, market acceptance of
PDTs, including BT-001, the risk that the results of previously
conducted studies will not be interpreted favorably by the FDA or
repeated or observed in ongoing or future studies involving Better
Therapeutics’ product candidates and other risks and uncertainties
included under the header “Risk Factors” in Better Therapeutics’
quarterly report on Form 10-Q for the quarter ended March 31, 2023
filed with the Securities and Exchange Commission (SEC) on May 11,
2023, and those that are included in any of Better Therapeutics’
subsequent filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230615216301/en/
Media Enquiries: Emma Williams
emma.williams@bettertx.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024